Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2024Journal of the Endocrine SocietyOpen Access

8494 A Case of Diabetic Ketoacidosis in Setting of COVID-19 Infection and SGLT-2 Inhibitor Use

View Full Paper
Ask AI
Bookmark
Share

Authors

NANora AbrahimiSBShreya BajpayAAAryan Abrahimi

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Abrahimi et al. (2024) studied this question.

synapsesocial.com/papers/68e5611fe2b3180350efe2e4https://doi.org/10.1210/jendso/bvae163.636
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Euglycemic Diabetic Ketoacidosis With COVID-19 Infection in Patients With Type 2 Diabetes Taking SGLT2 Inhibitors2020 · 55 citations
  2. 212621 Convergence Of Sglt2 Inhibitors And Glp1 Agonists: Unveiling The Recipe For Euglycemic Diabetic Ketoacidosis2024 · 1 citations
  3. 3914-P: Association of Sodium–Glucose Cotransporter 2 Inhibitors with Risk of Diabetic Ketoacidosis among Hospitalized Patients—A Multicentre Cohort Study2024
  4. 4Abstract TH825: Diabetic Ketoacidosis in Patients Treated with GLP-1 Agonists and SGLT2 Inhibitors: A Case Series and Clinical Implications in Cardiovascular Care2026
  5. 58243 Euglycemic Diabetic Ketoacidosis Unveiled: Delayed Presentation and Complications of SGLT-2 Inhibitor Therapy in a Multimorbid Patient - A Case Report2024 · 1 citations